Personalizing Hypertension Treatment?
نویسندگان
چکیده
منابع مشابه
The journey of personalizing gastric cancer treatment
Gastric cancer ranks the fourth most prevalent malignancy yet it is the second leading cause of cancer-related death. Every year, gastric cancer adds nearly 1 million new cancer cases, and 723,000 or 10% of cancer deaths to the global cancer burden. Approximately, 405,000 or 43% of the new cases and 325,000 or 45% of the deaths are in China, making gastric cancer a particularly challenging mali...
متن کاملToward personalizing treatment for depression: predicting diagnosis and severity
OBJECTIVE Depression is a prevalent disorder difficult to diagnose and treat. In particular, depressed patients exhibit largely unpredictable responses to treatment. Toward the goal of personalizing treatment for depression, we develop and evaluate computational models that use electronic health record (EHR) data for predicting the diagnosis and severity of depression, and response to treatment...
متن کاملMolecular biomarkers in colorectal cancer in pursuit of personalizing treatment
Introduction Recent and rapid advancements made in our understanding of the biology of colorectal cancer (CRC) has pointed towards a more personalized way of treating cancer, utilizing targeted treatment based on the tumour molecular profile. Epidermal Growth Factor Receptor (EGFR) has been found to play an important role in CRC tumorigenesis with its activation stimulating key signal transduct...
متن کاملBRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
PURPOSE Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGGs), and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAFV600E and mTOR inhibitors in gliomas carrying specific genetic alterations of the MAPK pathway. EXPERIMENTAL DESIGN We used human glioma lines containing BRAFV600E (adult hig...
متن کاملAntiplatelet agents and proton pump inhibitors – personalizing treatment
INTRODUCTION Antiplatelet therapy remains one of the cornerstones in the management of non-cardioembolic ischemic stroke. However, a significant percentage of patients have concomitant gastroesophageal reflux or peptic ulcer disease that requires acid-reducing medications, the most powerful and effective being the proton pump inhibitors (PPIs). Antiplatelet efficacy, at least in vivo, and parti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hypertension
سال: 2018
ISSN: 0194-911X,1524-4563
DOI: 10.1161/hypertensionaha.118.11107